IMI impact on antimicrobial resistance

Antimicrobial resistance is considered to be one of the top global public health and development threats, and it's estimated to cause more than 35 000 deaths per year in the EU. Despite this, few new antibiotics make it onto the market, meaning that there is an urgent need for innovative antimicrobials to treat resistant infections.

The COMBACTE projects - COMBACTE-NET, COMBACTE-MAGNET and COMBACTE-CARE formed public-private partnerships with the goal of addressing the challenges of clinical development of antibacterial medicines in response to antibiotic resistance. COMBACTE-NET focused on building strong clinical, laboratory and research networks to boost efficiency in testing new antibacterial agents; COMBACTE-MAGNET investigated the needs of critically-ill patients to develop better targeted treatments; and COMBACTE-CARE laid the foundations for the development of novel treatments against multi-drug resistant bacteria. This online webinar will highlight the impact that the COMBACTE projects are having in tackling antibiotic-resistant bacteria.

The COMBACTE projects are part of IMI's New Drugs for Bad Bugs programme, which comprises several projects that are finding solutions to the scientific, regulatory, and business challenges that are hampering the development of new antibiotics.